Trial results for the WW Clinic GLP-1 behavioral program for Obesity were posted on ClinicalTrials.gov on 2025-12-19, showing a mean weight loss of 27.41 pounds over 24 weeks.
Background
Obesity is a complex, chronic disease characterized by excessive body fat, which increases the risk of numerous health problems, including type 2 diabetes, heart disease, and certain cancers. Effective management often involves a combination of lifestyle interventions, such as dietary changes and increased physical activity, and medical treatments. Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a significant class of medications for weight management, demonstrating efficacy in promoting weight loss. Behavioral programs, like those offered by WeightWatchers, provide structured support and education, which can be crucial for sustaining long-term weight management. Combining a GLP-1-focused behavioral program with medical weight management support aims to enhance outcomes for individuals seeking to manage their weight.
Trial design
This completed study enrolled 180 participants with conditions including Weight Loss and Obesity. The trial evaluated the efficacy of the WeightWatchers (WW) GLP-1 behavioral program combined with WW Clinic (formerly known as Sequence medical weight management program) on weight loss and related outcomes. Participants were invited to take part and answer surveys at 0, 12, and 24 weeks. The study was a single-arm design, meaning all participants received the intervention, without a separate control or comparator group.
Key results
The trial reported several key measurements over 24 weeks for participants in the single arm:
- The mean change in weight from Week 0 to Week 24 was -27.41 pounds, with a Standard Deviation of 14.86 pounds.
- For blood pressure changes (Systolic and Diastolic) from Week 0 to Week 24, mean changes were observed as -5.66 mmHg (Standard Deviation 13.29) and -11.17 mmHg (Standard Deviation 14.96).
- For changes in quality of life scores from Week 0 to Week 24, mean changes were reported as -20.13 (Standard Deviation 17.79), -27.98 (Standard Deviation 22.5), -18.27 (Standard Deviation 23.1), -11.44 (Standard Deviation 17.99), and -12.08 (Standard Deviation 19.81) on a scale.
- Regarding "Weight Loss Percentage Change From Week 0 to Week 24," participant counts were reported as 161, 121, 81, and 20.
What this means
The results from this single-arm study suggest that the WW Clinic GLP-1 behavioral program, when combined with medical weight management, is associated with substantial weight loss. A mean reduction of 27.41 pounds in 24 weeks indicates a clinically meaningful impact for individuals with obesity. The observed reductions in blood pressure, with mean changes of -5.66 mmHg and -11.17 mmHg, are also positive indicators for cardiovascular health, a common comorbidity of obesity. Furthermore, the multiple reported improvements in quality of life scores, ranging from mean changes of -11.44 to -27.98, suggest a broad benefit beyond just weight reduction, potentially enhancing overall well-being for patients. These findings support the potential utility of integrated behavioral and medical approaches in obesity management.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06034457, titled "Testing the Effectiveness of WW Clinic GLP1", were posted on 2025-12-19 on clinicaltrials.gov.